137 related articles for article (PubMed ID: 20563869)
1. Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells.
Okabe S; Tauchi T; Ohyashiki K
Ann Hematol; 2010 Nov; 89(11):1081-7. PubMed ID: 20563869
[TBL] [Abstract][Full Text] [Related]
2. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.
Dai Y; Chen S; Venditti CA; Pei XY; Nguyen TK; Dent P; Grant S
Blood; 2008 Aug; 112(3):793-804. PubMed ID: 18505786
[TBL] [Abstract][Full Text] [Related]
3. Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.
Okabe S; Tauchi T; Kimura S; Maekawa T; Kitahara T; Tanaka Y; Ohyashiki K
PLoS One; 2014; 9(2):e89080. PubMed ID: 24586514
[TBL] [Abstract][Full Text] [Related]
4. Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells.
Fiskus W; Wang Y; Joshi R; Rao R; Yang Y; Chen J; Kolhe R; Balusu R; Eaton K; Lee P; Ustun C; Jillella A; Buser CA; Peiper S; Bhalla K
Clin Cancer Res; 2008 Oct; 14(19):6106-15. PubMed ID: 18829489
[TBL] [Abstract][Full Text] [Related]
5. Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia.
Donato NJ; Fang D; Sun H; Giannola D; Peterson LF; Talpaz M
Biochem Pharmacol; 2010 Mar; 79(5):688-97. PubMed ID: 19874801
[TBL] [Abstract][Full Text] [Related]
6. Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias.
Fei F; Stoddart S; Groffen J; Heisterkamp N
Mol Cancer Ther; 2010 May; 9(5):1318-27. PubMed ID: 20388735
[TBL] [Abstract][Full Text] [Related]
7. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
Kretzner L; Scuto A; Dino PM; Kowolik CM; Wu J; Ventura P; Jove R; Forman SJ; Yen Y; Kirschbaum MH
Cancer Res; 2011 Jun; 71(11):3912-20. PubMed ID: 21502403
[TBL] [Abstract][Full Text] [Related]
8. Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells.
Okabe S; Tauchi T; Tanaka Y; Kimura S; Maekawa T; Ohyashiki K
Cancer Cell Int; 2013 Apr; 13(1):32. PubMed ID: 23556431
[TBL] [Abstract][Full Text] [Related]
9. Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.
Fiskus W; Hembruff SL; Rao R; Sharma P; Balusu R; Venkannagari S; Smith JE; Peth K; Peiper SC; Bhalla KN
Breast Cancer Res Treat; 2012 Sep; 135(2):433-44. PubMed ID: 22825030
[TBL] [Abstract][Full Text] [Related]
10. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S
Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773
[TBL] [Abstract][Full Text] [Related]
11. MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.
Giles FJ; Swords RT; Nagler A; Hochhaus A; Ottmann OG; Rizzieri DA; Talpaz M; Clark J; Watson P; Xiao A; Zhao B; Bergstrom D; Le Coutre PD; Freedman SJ; Cortes JE
Leukemia; 2013 Jan; 27(1):113-7. PubMed ID: 22772060
[TBL] [Abstract][Full Text] [Related]
12. Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib).
Fei F; Lim M; Schmidhuber S; Moll J; Groffen J; Heisterkamp N
Mol Cancer; 2012 Jun; 11():42. PubMed ID: 22721004
[TBL] [Abstract][Full Text] [Related]
13. Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies.
Akahane D; Tauchi T; Okabe S; Nunoda K; Ohyashiki K
Cancer Sci; 2008 Jun; 99(6):1251-7. PubMed ID: 18429956
[TBL] [Abstract][Full Text] [Related]
14. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
Nimmanapalli R; Fuino L; Stobaugh C; Richon V; Bhalla K
Blood; 2003 Apr; 101(8):3236-9. PubMed ID: 12446442
[TBL] [Abstract][Full Text] [Related]
15. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.
Giles FJ; Cortes J; Jones D; Bergstrom D; Kantarjian H; Freedman SJ
Blood; 2007 Jan; 109(2):500-2. PubMed ID: 16990603
[TBL] [Abstract][Full Text] [Related]
16. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
17. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
Dasmahapatra G; Patel H; Nguyen T; Attkisson E; Grant S
Clin Cancer Res; 2013 Jan; 19(2):404-14. PubMed ID: 23204129
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
Gontarewicz A; Balabanov S; Keller G; Colombo R; Graziano A; Pesenti E; Benten D; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
Blood; 2008 Apr; 111(8):4355-64. PubMed ID: 18268096
[TBL] [Abstract][Full Text] [Related]
19. The discovery of the potent aurora inhibitor MK-0457 (VX-680).
Bebbington D; Binch H; Charrier JD; Everitt S; Fraysse D; Golec J; Kay D; Knegtel R; Mak C; Mazzei F; Miller A; Mortimore M; O'Donnell M; Patel S; Pierard F; Pinder J; Pollard J; Ramaya S; Robinson D; Rutherford A; Studley J; Westcott J
Bioorg Med Chem Lett; 2009 Jul; 19(13):3586-92. PubMed ID: 19447622
[TBL] [Abstract][Full Text] [Related]
20. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
Gontarewicz A; Balabanov S; Keller G; Panse J; Schafhausen P; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
Leuk Res; 2008 Dec; 32(12):1857-65. PubMed ID: 18514829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]